<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911108-0126</DOCNO><DOCID>911108-0126.</DOCID><HL>   Technology:   Imcera and Cambridge Biotech</HL><DATE>11/08/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   CBCX IMA</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>JOINT VENTURES (JVN)ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>ILLINOIS (IL)MASSACHUSETTS (MA)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   NORTHBROOK, Ill. -- Imcera Group Inc. said itsPitman-Moore animal health care unit signed a definitiveagreement with Cambridge Biotech Corp., Worcester, Mass., todevelop jointly animal vaccines and diagnostic products.Terms weren't disclosed.   A vaccine for the prevention of Lyme disease in dogs isthe first product the two companies are developing together,said Boyd D. Wainscott, president and chief executive officerof Pitman-Moore.</LP><TEXT>   As part of the agreement, Pitman-Moore acquired the rightto Cambridge's existing Lyme disease program and certainother vaccine technologies.</TEXT></DOC>